Literature DB >> 27184037

Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art.

Julie Bénard1,2, Solène Duros1, Hady El Hachem1, Charlotte Sonigo1, Christophe Sifer3, Michaël Grynberg1,2,4.   

Abstract

Quality of life of young cancer survivors has become a major issue. However, anticancer therapies can have a detrimental impact on fertility. It is now well-established that all patients should receive information about the fertility risks associated with their cancer treatment and the fertility preservation options available. Currently, oocyte or embryo banking after controlled ovarian hyperstimulation represents the most effective method for preserving female fertility. Over the past years innovative protocols of ovarian stimulation have been developed to enable cancer patients to undergo oocyte or embryo cryopreservation irrespective of the phase of the cycle or without exogenous follicle-stimulating hormone-related increase in serum estradiol levels. The present article reviews the different protocols of ovarian hyperstimulation for cancer patients, candidates for fertility preservation.

Entities:  

Keywords:  cancer; controlled ovarian hyperstimulation; embryo cryopreservation; fertility preservation; oocyte vitrification

Mesh:

Year:  2016        PMID: 27184037     DOI: 10.2217/fon-2016-0095

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  2 in total

Review 1.  Surgical Aspects of Ovarian Tissue Removal and Ovarian Tissue Transplantation for Fertility Preservation.

Authors:  M W Beckmann; R Dittrich; S Findeklee; L Lotz
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-10       Impact factor: 2.915

2.  In vitro maturation of immature oocytes for fertility preservation in cancer patients compared to control patients with fertility problems in an in vitro fertilization program.

Authors:  Irma Virant-Klun; Jure Bedenk; Nina Jancar
Journal:  Radiol Oncol       Date:  2021-12-22       Impact factor: 2.991

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.